Pemvidutide Explained
Synonyms: | ALT-801; MD-1373; SP-1373 |
Legal Status: | Investigational |
Cas Number: | 2538014-94-5 |
Unii: | A35F525WBG |
Kegg: | D12861 |
C: | 182 |
H: | 275 |
N: | 39 |
O: | 54 |
Pemvidutide (ALT-801) is an experimental dual GLP-1/glucagon receptor agonist developed by Altimmune.[1] [2] The drug reduced LDL-C in a clinical trial[3] and does not require dose titration as with GLP-1 mono agonists.[4]
Notes and References
- News: Beaney . Abigail . Obesity: Six trials to watch over the next 12 months . 5 December 2023 . Clinical Trials Arena . 30 June 2023.
- Bailey . Clifford J. . Flatt . Peter R. . Conlon . J. Michael . An update on peptide-based therapies for type 2 diabetes and obesity . Peptides . March 2023 . 161 . 170939 . 10.1016/j.peptides.2023.170939. free .
- Plutzky . Jorge . Harris . M. Scott S . Alonso . Cristina . Suschak . John . Noor . Mustafa . Ortiz . Pablo . Georges . Bertrand . Rader . Daniel J . Roberts . Scot S . Browne . Sarah K . Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators . Circulation . 8 November 2022 . 146 . Suppl_1 . 10.1161/circ.146.suppl_1.13440.
- Klein . Samuel . Nestor . John J. . Harris . M. Scott . Suyundikov . Anvar . Casper . Rob . Steele . Staci M. . Payne . Jacques D. . Krishnan . Vyjayanthi . Roberts . M. Scot . Browne . Sarah K. . 334-OR: Pemvidutide (ALT-801), a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity . Diabetes . 1 June 2022 . 71 . Supplement_1 . 10.2337/db22-334-OR.